Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today - Biomarin Pharmaceutical (NASDAQ:BMRN)Benzinga • 11/23/22
BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia APRNewsWire • 11/23/22
BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A ProgramPRNewsWire • 11/07/22
BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)PRNewsWire • 10/26/22
FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia APRNewsWire • 10/12/22
Wall Street Analysts See a 31% Upside in BioMarin (BMRN): Can the Stock Really Move This High?Zacks Investment Research • 10/12/22
BioMarin (BMRN) Starts Restructuring Moves to Increase EfficiencyZacks Investment Research • 10/07/22
BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ETPRNewsWire • 10/04/22
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDAPRNewsWire • 09/29/22
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarinInvestors Business Daily • 09/15/22
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent ReportPRNewsWire • 09/15/22